BRAF and melanoma: Beginning in 2011, novel therapies, including immunotherapy with immune checkpoint inhibitors CTLA-4 or PD-1, as well as targeted therapy with BRAF and MEK inhibitors, have become a key breakthrough in the clinical landscape of melanoma treatment (4).